Skip to main content

Table 5 Response by irAE and Disease Type

From: Improved survival and tumor control with Interleukin-2 is associated with the development of immune-related adverse events: data from the PROCLAIMSM registry

Best Response

mM

mRCC

 

irAE, n = 84

No irAE, n = 539

irAE, n = 46

No irAE, n = 873

Complete Response (CR)

5(6.0%)

23(4.3%)

3 (6.5%)

44(5.0%)

Partial Response (PR)

27 (32.1%)

89 (16.5%)

10 (21.7%)

153 (17.5%)

Stable Disease (SD)

29 (34.5%)

167 (31.0%)

19 (41.3%)

317 (36.3%)

Progressive Disease (PD)

19 (22.6%)

211 (39.1%)

13 (28.3%)

262 (30.0%)

Missing

4 (4.8%)

49 (9.1%)

1 (2.2%)

97 (11.1%)

CR + PR (n,%)

32 (38.1%)

112 (20.8%)

aP = 0.0058

13 (28.3%)

197 (22.6%)

aP = 0.5999

CR + PR+ SD (n, %)

61 (72.6%)

279 (51.8%)

bP = 0.0013

32 (69.6%)

514 (58.9%)

bP = 0.6263

  1. aFisher’s exact test comparing best response by irAE
  2. bFisher’s exact test comparing tumor control by irAE